Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/30495
|
| Title: | 探索創新智慧資本對新產品開發績效之影響 -個案研究以製藥產業為例- |
| Authors: | 許秀菁
Hsiu-Ching Hsu |
| Contributors: | 李仁芳教授
J. F. Lee
許秀菁
Hsiu-Ching Hsu |
| Keywords: | 創新智慧資本
新產品開發
製藥產業
個案研究
Intellectual Capital
New Product Development
Pharmaceutical Industry
Case Study |
| Date: | 2002 |
| Issue Date: | 2009-09-12 12:16:17 (UTC+8) |
| Abstract: | 對製藥產業而言，不斷推出創新產品是其價值創造的最大動力。另一方面，市場之競爭與價格限制之壓力使所有的製藥業者莫不將提高研發的績效視為企業維持高成長的關鍵途徑。因而製藥企業一直面臨的巨大壓力便是要能快速、確實推出安全有效的新藥上市。隨著競爭模式的轉移，無形資產及知識創造之價值將是決勝的關鍵。受限於本土藥品市場規模的限制與有限的研發能量，本土製藥企業之新藥研發大多以發展階段的新藥開發為主而非風險大、時程長的新藥研究。於是瞭解智慧資本的創造、加值、運用與管理對製藥產業新產品開發績效之影響也將更為關鍵。本研究先就智慧資本之文獻與各種衡量模式進行歸納，並引用Skandia智慧資本導航者之架構，分別以人力資本、流程資本、創新資本與關係資本四個構面評量企業之創新智慧資本之內涵與建置，並試圖瞭解本土製藥產業創新智慧資本對新產品開發績效之影響，期能對我國產製藥產業智慧資本之管理方向提出建議，以提供業界進行創新智慧資本管理與發展之參考。
The lifeblood of the pharmaceutical industry is its ability to produce innovative products. Additionally, both the heavy competition in the market and the trend of cutting price by the health insurance payers also force the industry turns their focus on increasing the performance of R&D to maintain the high growth rate. Therefore, how to launch a safe and effective new drug in a shortest time is a great challenge to the industry. Along with the changing of the core competitive advantages, the value of the intangible assets and knowledge creation become the key success factors. Linking intellectual capital management with R&D activities in pharmaceutical companies would be a critical factor in enhancing R&D performance. For a local pharmaceutical, limited by the market size and the R&D ability, the R&D activities would be more on the development phase than research phase. The relationship between intellectual capital with new product development would be more critical especially in this knowledge-base pharmaceutical industry. By literature review and adopting the intellectual capital assessment model of the Skandia Nevigator, the study divides the intellectual capital into human capital, processes capital, innovation capital and relationship capital and try to find the elements of innovative intellectual capital related to new drug development in a local pharmaceutical company. It also tries to find out how a local pharmaceutical company creates and manages its innovative intellectual capital. The research results show the current situation about intellectual capital of the case and will be provide a reference for the industry and further research.
"第 一 章、 緒論 1
第 一 節、 研究背景與動機 1
第 二 節、 研究目的與問題 3
一、 找出我國製藥產業在新產品開發之創新智慧資本要素 3
二、 探討創新智慧資本要素對新產品開發績效之影響 3
三、 對我國製藥產業之新產品開發創新智慧資本管理方向提出建議 3
第 二 章、 文獻探討 3
第 一 節、 前言 3
第 二 節、 智慧資本相關理論 3
一、 智慧資本研究的發展 4
二、 智慧資本之定義 5
三、 智慧資本之內涵 9
第 三 節、 智慧資本的之衡量與指標 19
一、 Edvinsson & Malone (1997) 20
二、 Thomas Stewart (1997) 21
三、 Roos et al. (1998) 22
四、 Sullivan (1998) 22
五、 吳思華(2002) 23
六、 無形資產之衡量 23
七、 智慧資本衡量與指標小結 26
第 四 節、 智慧資本的管理 27
一、 Brooking (1996) 27
二、 Nick Bontis (1996) 28
三、 Edvinsson & Malone (1997) 29
四、 Sullivan (1998) 30
五、 吳安妮(2001) 32
六、 智慧資本管理的發展小結 32
第 五 節、 生技製藥產業智慧資本之研究 33
一、 蘊育美國生技產業的智慧資本 33
二、 生技製藥產業新藥研發之知識資本 34
三、 製藥產業知識資本之衡量 35
四、 我國對生技製藥產業相關智慧資本之研究 36
第 三 章、 研究方法 37
第 一 節、 研究設計與變數說明 37
一、 研究流程與研究架構 37
二、 創新智慧資本研究變數說明 39
三、 新產品開發變數說明 41
第 二 節、 資料蒐集方法 42
第 三 節、 研究對象與研究限制 42
一、 研究對象 42
二、 研究限制 43
第 四 章、 製藥產業 43
第 一 節、 全球製藥產業 43
一、 全球製藥產業市場概況 44
二、 全球製藥產業之特性 45
三、 全球製藥產業之發展趨勢 47
第 二 節、 製藥產業之價值創造 50
第 三 節、 製藥研發 52
一、 製藥產業研發價值鏈 52
二、 製藥產業之創新 54
三、 製藥產業之研發投入與產出 56
四、 製藥產業研發的挑戰 60
五、 製藥產業研發的關鍵成功因素 66
第 四 節、 台灣製藥產業之特性與趨勢 70
一、 台灣製藥產業之定義與範圍 70
二、 台灣製藥產業之市場現況 72
三、 台灣製藥產業之產業價值鏈 72
四、 台灣製藥產業之特性 75
五、 台灣製藥產業面臨之衝擊與困難 78
第 五 章、 個案公司介紹 81
第 一 節、 個案公司簡介 81
一、 1960 ~ 1995年之學名藥廠 82
二、 1996 ~ 1999年之品牌學名藥廠期 82
三、 2000 ~ 新藥開發藥廠 85
第 二 節、 經營理念與願景 86
一、 經營理念 86
二、 願景 87
第 三 節、 個案公司之定位與經營策略 87
一、 個案公司之定位 88
二、 個案公司之關鍵成功要素 88
三、 個案公司之經營策略 88
第 四 節、 經營概況 89
一、 經營團隊 90
二、 銷售概況 90
三、 獲得獎項 93
第 五 節、 研發概況與研發策略 93
一、 研發概況 93
二、 研發策略 94
第 六 章、 研究結果與討論：製藥研發智慧資本之個案研究 95
第 一 節、 財務指標 95
一、 智慧資產價值 95
二、 新產品開發財務績效指標 98
第 二 節、 人力資本 99
一、 新產品開發團隊 99
二、 新產品開發團隊之培訓 102
三、 本土製藥企業新產品開發之人力資本要素 107
第 三 節、 流程資本 110
一、 新產品開發流程 110
二、 新產品開發之管理 113
三、 新產品開發之知識管理 117
四、 資訊科技之應用 120
五、 本土製藥企業新產品開發之流程資本要素 121
第 四 節、 創新資本(更新與開發焦點) 125
一、 研究發展投入 125
二、 創新與創造力 127
三、 創意產生機制 132
四、 本土製藥企業新產品開發之創新資本要素 133
第 五 節、 關係資本 138
一、 顧客關係資本 138
二、 研發合作網路關係資本 140
三、 企業委外研發夥伴關係資本 143
四、 本土製藥企業新產品開發之關係資本要素 145
第 七 章、 結論與建議 148
第 一 節、 結論 148
一、 財務構面 150
二、 人力資本 151
三、 流程資本 152
四、 創新資本 154
五、 關係資本 156
第 二 節、 研究限制與建議 157
附錄 一、 Edvinsson & Malone (1997) Skandia智慧資本報告之內涵與指標 158
附錄 二、 網際網路產業智慧資本衡量要項 161
附錄 三、 研發機構智慧資本的衡量指標 163
附錄 四、 個案公司企業沿革 165
附錄 五、 個案公司1998~2003年重要研究發表文獻 167
參考資料 168 |
| Reference: | 1. 中央通訊社新聞 (2000/5/30) . http://www.doctor.com.tw/article.asp?channelid=21&serial=903
2. 王美音譯, Dorothy Leonard – Barton. Wellsprings of Knowledge – Building and Sustaining the Sources of Innovation (知識創新之泉 遠流出版)
3. 王莫昀 中央社記者台北2003/03/13電. http://news.yam.com/cna/fn/news/200303/200303130390.html
4. 宋偉航譯, Stewart, Thomas A., (1998). Intellectual Capital (智慧資本 – 資訊時代的企業利基) 智庫文化出版
5. 林大容 譯, Edvinsson, L. and Malon M. (1997), ‘Intellectual Capital: realizing your company’s true value by finding its hidden roots (智慧資本 – 如何衡量資訊時代無形資產的價值). 臉譜出版
6. 吳思華 (1996). 策略九說
7. 吳思華等（2000）,網際網路智慧資本衡量與發展措施,經濟部工業局軟體五年發展計畫.
8. 吳安妮(2001) 我國產業智慧資本個案研究(一)，我國產業智慧貨本理論與實務研討會
9. 吳安妮 (2003), 智慧資本之衡量與管理. 92 經濟部「跨領域科技管理研習班」演講稿
10. 巫文玲 (2003), 生技醫藥速報, ITISDCB-0453-F128(92)
11. 孟慶國、田克錄等譯, Klein D. A. The Strategic Management of Intellectual Capital (智力資本的策略管理，米娜貝爾出版)
12. 個案公司公開說明書
13. 創業投資電子報第六九三號 92/4/22-News
14. 創業投資電子報第六九四號 92/4/23-News
15. 楊子江、王美音譯, Nonaka I. & Takeuchi H. The Knowledge-Creating Company. (創新求勝 遠流出版)
16. 劉靜美 (2001)，「衡量研發機構的智慧資本之研究：以工研院生醫工程中心為例」碩士論文研究，國立政治大學科技管理研究所
17. 劉靜美(2001)，「衡量研發機構的智慧資本之研究：以工研院生醫工程中心為例」碩士論文研究，國立政治大學科技管理研究所
18. 2001製藥產業年鑑. 財團法人生物技術開發中心
19. 2002 Knowledge Economy Conference, ‘International Pharmaceutical Research and Development External Relationships and Alliances - A Way Forward for New Zealand’, 19 March 2002, Conference Papers
20. Bell, C. R. (1997), "Intellectual Capital," Executive Excellence, 14(1), 15, 1997.
21. Bontis, N. (1996), `There`s a price on your head: Managing intellectual capital strategically`, Business Quarterly, summer, p.41-47
22. Bontis, N. (1998). Intellectual Capital: An Exploratory Study that Develops Measures and Models, Management Decision, 36(2).
23. Bowonder B, S. Yadav and B. Sunil Kumar (2000), R&D Spending Patterns of Global Firms, Industrial Research Institute Inc.,
24. Brooking, A. (1996), Intellectual Capital, London: International Thomson Business Press, 1996.
25. Brooking, A., Board, P. and Jones, S. (1998), "The Predictive Potential of Intellectual Capital," International Journal of technology Management, Vol. 16, No. 1/2/3, 1998, pp. 115-125.
26. Burrill G.S., Biotech (2001) – the biotechnology industry annual report, Burrill & Company
27. Capron, H (1994). “Technology Competition and Strate4gy of Firms inside the Triad”, in Management of Technology IV, T. M. Khalil and A. Bayrakar (eds.), Industry Engineering and management Press, Norcross, Georgia, 1994, p.467-77
28. Cooper John. (2000), CMA management, Oct. 2000, p.22-27
29. Cutting Edge Information (2003), “Managing Key Opinion Leader Relationships”
30. Datamonitor (2001), `Maximizing R&D Productivity: Getting More Bang for Your R&D Buck`, March 2001
31. David Skyrme Associates (1997), `Measuring Intellectual Capital: a plethora of methods`, Management Insights No.24
32. Dzinkowski, Ramona (2000), ‘Mission Possible’, CMA Management 74, no. 1 (February 2000): 36-40
33. Editors, ‘A New Rx for Corporate Disclosure’, PriceWaterHouseCoopers ValuereportingTM
34. Edvinsson, L. and P. Sullivan. (1996). “Developing a Model for Managing Intellectual Capital”, European Management Journal, 14, 4.
35. Edvinsson L. and Malone M. (1997) Intellectual capital: realizing your company`s true value by finding its hidden brainpower. New York: Harper Business
36. Edvinsson, L. (1997). Developing a Model for Managing Intellectual Capital in Longe Range Planning, 30(3), pp.320-321 and pp.366-373.
37. Edvinsson, L. & Malone, M.S. (1997). Intellectual Capital, Paitkus, London.
38. European Management Journal (1996 vol 14)
39. FDA
40. Feiwel, G.R. (1975) The Intellectual Capital of Michael Kalecki: A Study in Economic Theory and Policy, Knoxville: The University of Tennessee Press, p.17
41. Financial Times Pharmaceutical Conference, December 2001. http://www.ftconferences.com/
42. Graef Jean (1997), ‘Measuring intellectual assets’, http://www.montague.com/le/le1096.html
43. Henderson R., Cockburn I. (1994), Measuring Competence? Exploring Firm Effects in Pharmaceutical Research. Strategic Management Journal, Vol. 15, 63-84
44. Hudson William (1993), Intellectual Capital: How to Build It, Enhance It, Use It. Published by John Wiley & Sons; (May 1993)
45. IMS Health Taiwan
46. Itami, H. (1987). Mobilizing Invisible Assets. Boston: Harvard University Press.
47. Johnson, W. H. A. (1999), "An integrative taxonomy of intellectual capital: measuring the stock and flow of intellectual capital components in the firm", International Journal of Technology Management, Vol. 18, No. 5/6/7/8, 1999, pp. 562-575.
48. Jung Jeffrey (2000). Creating Value Through Innovation. IBM Institute for Business Value, December 2000
49. Karl-Erik Sveiby (1997), http://www.sveiby.com.au/articles/EmergingStandard.html
50. Karl-Erik Sveiby (2001, 2002), `Methods for Measuring Intangible Assets`, Jan 2001, updated April 2001, May 2002, October 2002.
51. Kaplan, R.S.; Norton, D.P. (1996). The Balanced Scorecard; Translating strategy into action. Harvard Business School Press, Boston.
52. Kelly Brian, Pipeline and Portfolio Management Balancing Multiple Projects and Limited Resources - Case Studies. http://www.managementroundtable.com/Event_Center/PPM03/ADV-PPM03-casestudies.html#Merck
53. Lev Baruch, Mintz S.L. (1999), Seeing is Believing - A Better Approach to Estimating Knowledge Capital,CFO Magazine February, http://www.cfoasia.com/archives/9905-42.htm%
54. Lynne G. Zucker, Michael R. Darby, Marilynn B. Brewer (1994), Intellectual Capital and the Birth of US Biotechnology Enterprise, NBER Working Paper Series no.4653
55. Lynn, B. (1998). “Performance evaluation in the new economy”, International Journal of Technology Management, 16, 1/2/3, 162-176.
56. MA van den Haak, CE Lumley & JAN McAuslane (2001), Pharmaceutical Investment and Output Survey 2001. March 2003, CMR02-171AR
57. Madanmohan Rao (2003), Leveraging Pharmaceutical Knowledge, March 03, 2003. http://www.destinationkm.com/print/default.asp?ArticleID=1037
58. Market access for new medicines: Are companies changing their strategies? http://www.cmr.org/pdfs/R&D33.pdf
59. Masoulas, V. (1996) ‘Organizational requirements definition for designing systems to support intellectual capital management’. Proceedings of the Second World Conference on Integrated Design and Process Technology, Austin TX, USA
60. Masoulas, Vasilis (1998), "Organizational requirements definition for intellectual capital management", International Journal of Technology Management, Vol.16, Nos.1/2/3, 1998, pp.126-143.
61. Omta, S. W. F.; Van Engelen, M. L. (1998), ‘Preparing for the 21st century’, Research Technology Management v. 41 (Jan./Feb. 1998) p. 31-5
62. Patrick H. Sullivan (2000), ‘Value-Driven Intellectual Capital’
63. PhRMA 2000, FDA
64. PhRMA annual report 2001-2002
65. Rafiq Mohammed; Saxon Tim (2000), `R&D and marketing integration in NPD in the pharmaceutical industry`, European Journal of Innovation Management; 2000, Volume 3 No. 4, p222-231
66. Roos, Johan (1998) "Exploring the Concept of Intellectual Capital(IC)", Long Range Planning, February,Vol.31,pp.150-153
67. Ross et al. (1998) Intellectual Capital. New York Press. P.63
68. Roos, J., Roos, G., Dragonetti, N. and L. Edvinsson. (1998). Intellectual Capital : Navigating in the New Business Landscape, New York: New York University Press.
69. Shantha Liyanage (1999), Towards a fourth generation R&D management model-research networks in knowledge management. Int. J. Technology Management, Vol 18; No.3/4. p372-392
70. Skandia. (1994). “Visualizing Intellectual Capital in Skandia”, A supplement to Skandia’s 1994 Annual Report, Sweden.
71. Skandia. (1995a). “Renewal and Development: Intellectual Capital”, A supplement to Skandia’s 1995 Interim Annual Report, Sweden.
72. Skandia. (1995b). “Value-Creating Processes: Intellectual Capital”, A supplement to Skandia’s 1995 Annual Report, Sweden.
73. Skandia. (1996a). “Power of Innovation: Intellectual Capital”, A supplement to Skandia’s 1996 Interim Annual Report, Sweden.
74. Skandia. (1996b). “Customer Value”, A supplement to Skandia’s 1996 Annual Report, Sweden.
75. Skandia. (1997). “Intelligent Enterprising”, A Supplement to Skandia’s 6-Month Interim Report, Sweden.
76. Skyrme D. Associates (1997), `Measuring Intellectual Capital: a plethora of methods`, Management Insights No.24
77. Sveiby, K.E. (1997). The New Organizational Wealth. Berrett-Koehler Publishers, San Francisco.
78. Sveiby, K.E. (2001a). Methods for Measuring Intangible Assets, http://www.sveiby.com.au/IntangibleMethods.htm, 18-5-2001.
79. Sveiby, K.E. (2001b). The Balanced Score Card (BSC) and the Intangible Assets Monitor – a comparison, http://www.sveiby.com.au/IntangAss/BSCandIAM.html, 18-5-2001.
80. Syrme D. J. (1999), ‘From Measurement Myopia to Knowledge Leadership’, www.skyrme.com/ppt/ access/sld023.htm
81. Stefano Vincenti, Knowledge Management IT Strategies - For the Pharmaceutical and Biotech Industries, www.novonordisk-it.com/resources/ km+conference+nice+-+stefano+vincenti+v1.pdf
82. Stephen A Bernhardt; George A McCulleyv (2000), Knowledge management and pharmaceutical development teams: Using writing to guide scienc. Technical Communication. 22-34 47, no. 1 p. 22-34
83. Stuart Walker, Challenging Issues for Pharma R&D, http://www.cmr.org/firstlaunches/documents/DrugDevtarticle.pdf
84. Stewart, Thomas A. (1991). “Brainpower: How Intellectual Capital is Becoming America’s Most Valuable Asset”. FORTUNE. June 3, 1991. pp.44-60.
85. Stewart, Thomas A. (1994). “Your Company’s Most Valuable Asset: Intellectual Capital” FORTUNE. October 3, 1994. pp.68-74.
86. Stewart, Thomas A. (1997). Intellectual Capital: The New Wealth of Organizations. Doubleday/Currency: New York.
87. Sullivan, P. and L. Edvinsson. (1996). “A model for managing intellectual capital”, In R. Parr and P. Sullivan (Eds.), Technology Licensing, New York: John Wiley & Sons.
88. Sullivan (1998), Profiting from Intellectual Capital: Extracting Value from Innovation
89. Sullivan P. H. (2000). Value-Driven Intellectual Capital – How to Convert Intangible Corporate Assets Into Market Value. Published by John Wiley & Sons, Inc.
90. Sveiby, K.E. (1997). The New Organizational Wealth: Managing and Measuring Knowledge-Based Assets. Berrett-Koehler: New York.
91. Teece, David J.(1998), "Capturing Value from Knowledge Assets：The New Economy, Markets For Know-how, and Intangible Assets", California Management Review, spring, 1998
92. Tufts Center for the Study of Drug Development "Outlook 2002."
93. Tufts CSDD Impact Report Volume 2 • December 2000
94. Walter W. Powell (1998), Learning from Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries, California Management Review. Vol 40, No 3, p228-240
95. Ulrich Dave (1998), `Intellectual capital = competence x commitment`, Sloan Management Review, Wntr, 1998 |
| Description: | 碩士
國立政治大學
經營管理碩士學程(EMBA)
90932910
91 |
| Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0090932910 |
| Data Type: | thesis |
| Appears in Collections: | [經營管理碩士學程EMBA] 學位論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| index.html | 0Kb | HTML2 | 352 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
